Getting a Wegovy prescription in the United States requires a licensed prescriber, specific BMI-based eligibility, and usually an insurance prior-authorization process. Wegovy (semaglutide 2.4 mg weekly injection) is an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management and, since March 2024, for cardiovascular risk reduction in adults with established heart disease and obesity or overweight.
FDA-Approved Uses
Wegovy has two main FDA indications in adults:
- Chronic weight management alongside a reduced-calorie diet and increased physical activity, in adults with BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.
- Cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial showing a 20 percent reduction in major adverse cardiovascular events.
Wegovy is also approved for adolescents aged 12 and older with a BMI at or above the 95th percentile for age and sex. It is not approved for cosmetic weight loss in people who do not meet BMI criteria.
Eligibility Criteria
Before writing a Wegovy prescription, clinicians typically confirm:
- Current height, weight, and BMI calculation.
- Presence of a qualifying weight-related condition if BMI is 27 to 29.9.
- Absence of contraindications, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or prior serious hypersensitivity to semaglutide.
- Pregnancy status — Wegovy is not recommended during pregnancy.
- Current medications that could interact or overlap, especially other GLP-1 agonists or insulin.
- A plan for diet, physical activity, and behavioral support alongside the medication.
The Prescribing Process
A typical path to a Wegovy prescription looks like this:
- Initial visit with a primary care physician, obesity medicine specialist, endocrinologist, or telehealth clinician licensed in your state.
- Medical history and labs as clinically indicated — often fasting glucose, A1C, lipid panel, thyroid and kidney function. Review our A1C levels guide to understand those numbers.
- Shared decision on goals — weight, waist circumference, cardiovascular risk, quality of life.
- Prior authorization submission to your insurer if required, including documentation of BMI, comorbidities, and previous weight-loss attempts.
- Dose escalation plan starting at 0.25 mg weekly, with monthly increases per the FDA label.
- Follow-up every 4 to 12 weeks to monitor tolerance, weight, and metabolic markers.
Insurance Coverage in 2025
| Payer Type | Typical Coverage | Key Conditions |
|---|---|---|
| Commercial insurance | Varies by plan | Often requires prior authorization and BMI documentation |
| Medicare Part D | Covered only for cardiovascular risk indication | Requires established cardiovascular disease |
| Medicaid | State-by-state | Some states cover anti-obesity medications, others exclude them |
| VA / Tricare | Formulary-dependent | Often stepwise with prior non-pharmacologic attempts |
| Employer self-funded | Highly variable | Some carve out anti-obesity coverage entirely |
Call your insurer and ask specifically whether semaglutide 2.4 mg (Wegovy) is covered for chronic weight management, cardiovascular risk reduction, or both, and what documentation the prior authorization needs.
Costs and Savings Programs
Wegovy’s list price is roughly 1,350 dollars per 28-day supply, though actual pharmacy prices differ. Novo Nordisk offers a commercial savings card that may lower monthly costs for eligible patients with private insurance; federal program beneficiaries (Medicare, Medicaid, TRICARE) are usually excluded from manufacturer coupons by law. Patient-assistance programs exist for those who meet income thresholds and lack coverage. Always verify current terms on the manufacturer’s website at the time of your prescription.
Safety and Monitoring
Common side effects, per the FDA prescribing information, include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, and injection-site reactions. Gastrointestinal effects are usually most noticeable during dose escalation. Important warnings include:
- Boxed warning for thyroid C-cell tumor risk based on rodent studies; avoid in those with MTC or MEN 2 history.
- Risk of acute pancreatitis — stop if persistent severe abdominal pain develops.
- Gallbladder disease, acute kidney injury (often related to dehydration from nausea or vomiting), diabetic retinopathy complications in some patients with type 2 diabetes, hypoglycemia when combined with insulin or sulfonylureas, heart rate elevation, suicidal behavior or ideation to monitor, and possible aspiration risk around anesthesia.
Only your prescriber can decide if Wegovy is appropriate and how to manage side effects. Our treatment hub discusses broader obesity and prediabetes care options.
Lifestyle Still Matters
Wegovy works best as part of a structured plan that includes balanced nutrition, regular physical activity, sleep, and behavioral support. In the STEP trials, participants who combined semaglutide with intensive lifestyle counseling achieved approximately 14 to 17 percent average body weight reduction over 68 weeks — outcomes that depend on continuing the medication and the habits together.
The Bottom Line
A Wegovy prescription is a structured clinical process that starts with BMI-based eligibility, runs through prior authorization, and ends with a dose-escalation plan and ongoing monitoring. Coverage varies across insurers, and new cardiovascular labeling has expanded access for some adults with heart disease. Work closely with a qualified prescriber to confirm that Wegovy fits your medical profile, goals, and financial reality.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional about any medical condition, device, or treatment plan.
